Two of them received targeted therapy (patient #8 with low-grade glioma and proven pathogenic variant in BRAF gene in the tumor tissue received MEK and BRAF inhibitors; patient #13 with NF2 was treated by VEGF and mTOR inhibition due to the known genetic disease) contrasted to other patients who received conventional chemotherapy. The gene discussed is MAP2K7; the disease is neoplasm.